BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Pancreatic cancer clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for pancreatic cancer: 408 (275 sponsors; 55 newly posted in the last 180 days, 18 stopped in the last 180 days; 30 new-entrant sponsors). Momentum score 10, rank 70 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 9, Phase 1 133, Phase 2 170, Phase 3 46, Phase 4 1, N/A 49.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Revolution Medicines, Inc. RVMD | 11 | P2 3, P3 5, P1 3 | 2 | 2 |
| Jiangsu HengRui Medicine Co., Ltd. | 4 | P2 1, P3 3 | 1 | 1 |
| Exelixis EXEL | 3 | P3 2, P1 1 | 1 | 1 |
| ITM Solucin GmbH | 2 | P3 2 | 0 | 0 |
| Jiangxi Kvvit Pharmaceutical Co., Ltd. new entrant | 2 | P3 2 | 2 | 0 |
| Astellas Pharma Global Development, Inc. | 7 | P1 3, P3 1, P2 3 | 0 | 2 |
| Bristol-Myers Squibb BMY | 7 | P3 1, P2 4, P1 2 | 1 | 0 |
| Akeso | 5 | P1 1, P2 3, P3 1 | 0 | 2 |
| Incyte Corporation INCY | 4 | P3 1, P1 2, P2 1 | 0 | 2 |
| Pfizer PFE | 4 | P1 3, P3 1 | 1 | 0 |
| Evopoint Biosciences Inc. | 3 | P3 1, P2 1, P1 1 | 2 | 1 |
| Genfleet Therapeutics (Shanghai) Inc. | 3 | P2 2, P3 1 | 2 | 0 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 3 | P2 1, P1 1, P3 1 | 2 | 1 |
| Angiodynamics, Inc. ANGO | 2 | NA 1, P3 1 | 0 | 0 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2 | P3 1, P2 1 | 0 | 0 |
| Immuneering Corporation IMRX | 2 | P2 1, P3 1 | 0 | 0 |
| Innovent Biologics (Suzhou) Co. Ltd. | 2 | P2 1, P3 1 | 0 | 0 |
| Qilu Pharmaceutical Co., Ltd. | 2 | P3 1, P1 1 | 0 | 0 |
| RayzeBio, Inc. | 2 | P1 1, P3 1 | 0 | 2 |
| Arcus Biosciences, Inc. RCUS | 1 | P3 1 | 0 | 0 |
| Crinetics Pharmaceuticals Inc. | 1 | P3 1 | 0 | 0 |
| CSPC Ouyi Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Eleison Pharmaceuticals LLC. | 1 | P3 1 | 0 | 0 |
| ElmediX new entrant | 1 | P3 1 | 1 | 0 |
| FutureGen Biopharmaceutical (Beijing) Co., Ltd | 1 | P3 1 | 0 | 0 |
New-entrant sponsors: Jiangxi Kvvit Pharmaceutical Co., Ltd., ElmediX.
Recently stopped trials
- NCT05194735 Alaunos Therapeutics - terminated: Sponsor halted enrollment on 14 Aug 2023 for business reasons after a Board review of funding needs and permanently discontinued TCR-T cell Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
- NCT06756035 Context Therapeutics Inc. - terminated: The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termi CT-95 in Advanced Cancers Associated With Mesothelin Expression
- NCT06882746 Boehringer Ingelheim - terminated: Sponsor decision A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
- NCT06364696 Astellas Pharma Inc - terminated: Company's strategic decision A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
- NCT05124743 Alaunos Therapeutics - terminated: Screening moved into TCR001-201 under Amendment 4 (IRB approved 20 Jan 2023; implemented February 2023). Previously enrolled participants co HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumor
- NCT06091930 Boehringer Ingelheim - terminated: Sponsor decision A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Can
- NCT04638751 Persephone Biosciences - suspended: Currently no funding to continue study. ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
- NCT07488884 ImmunityBio, Inc. - withdrawn: The sponsor has changed the development plans which is not for safety reasons. Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combinat
- NCT05494697 AIM ImmunoTech Inc. - suspended: A business decision to place screening/enrollment on hold. Study redesign/amendment pending additional Ampligen-related data from an ongoing Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
- NCT05827614 Boundless Bio, Inc. - terminated: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safe Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With
- NCT04123574 BioXcel Therapeutics Inc - withdrawn: No longer relevant to field A Pilot Study of BXCL701 in Patients With Pancreatic Cancer
- NCT06528093 Boehringer Ingelheim - terminated: A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Ta
- NCT05451849 TCR2 Therapeutics - terminated: No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear signal of robust clinical activity. A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
- NCT04348643 Chongqing Precision Biotech Co., Ltd - withdrawn: The sponsor requested to terminate the study. Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer
- NCT06585488 BeOne Medicines - terminated: The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competi A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Met
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P1/P2 | BeyondBio Inc. | NCT03579836 Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer | Locally Advanced or Metastatic Pancreatic Cancer | recruiting | 75 |
| 2026-11-30 est. | P2 | Ranok Therapeutics (Hangzhou) Co., Ltd. | NCT07303465 To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. | KRAS G12D Mutations; Pancreatic Ductal Adenocarcinoma (PDAC) | recruiting | 60 |
| 2026-12 est. | P2 | SynerGene Therapeutics, Inc. | NCT02340117 Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | Metastatic Pancreatic Cancer | active not recruiting | 28 |
| 2026-12 est. | P3 | GC Cell Corporation | NCT04969731 Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | recruiting | 408 |
| 2026-12 est. | P1/P2 | A2 Biotherapeutics Inc. | NCT05736731 A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression | Solid Tumor, Adult; Solid Tumor; Pancreatic Cancer; Pancreatic Neoplasms; Pancreas Cancer; Non Small | active not recruiting | 160 |
| 2026-12 est. | P2 | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07233850 A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | Gastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC); Pancreatic Duc | not yet recruiting | 300 |
| 2026-12-15 est. | P2 | EXACT Therapeutics AS | NCT06850623 Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer | Locally Advanced Pancreatic Adenocarcinoma | recruiting | 25 |
| 2026-12-25 est. | P3 | Jiangsu Healthy Life Innovation Medical Technology Co., Ltd | NCT05653453 Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer | Locally Advanced Pancreatic Cancer | recruiting | 512 |
| 2026-12-30 est. | P1/P2 | Akeso | NCT06646055 AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | active not recruiting | 110 |
| 2026-12-30 est. | P1/P2 | Astellas Pharma Global Development, Inc. | NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. | Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Metasta | active not recruiting | 240 |
| 2026-12-31 est. | P2 | Partner Therapeutics, Inc. | NCT02912949 A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion; Pancreatic Cancer Harboring NRG1 F | active not recruiting | 250 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P2 | Allist Pharmaceuticals, Inc. | NCT06008288 A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. | KRAS P.G12C; Pancreatic Cancer; Solid Tumor | recruiting | 88 |
| 2026-12-31 est. | P2 | Jazz Pharmaceuticals JAZZ | NCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endome | recruiting | 200 |
| 2026-12-31 est. | P1/P2 | Evopoint Biosciences Inc. | NCT06799637 Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | Advanced Solid Tumors; Pancreatic Carcinoma; Ovarian Cancer; Cervical Cancers | recruiting | 350 |
| 2027-01-01 est. | P1/P2 | Second Life Therapeutics | NCT07341737 SL-28 for Advanced Solid Tumours | Head & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cance | recruiting | 60 |
| 2027-02 est. | P1/P2 | Lumicell, Inc. | NCT02584244 Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers | Colorectal Cancer; Pancreatic Cancer; Esophageal Cancer; Gastric Cancer | active not recruiting | 66 |
| 2027-02 est. | P1/P2 | GI Innovation, Inc. | NCT07172802 A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor; Metastatic Solid Tumor; Non-small Cell Lung Cancer (NSCLC); Head and Neck (HNS | recruiting | 102 |
| 2027-02-01 est. | P1/P2 | Amplia Therapeutics Limited | NCT05355298 ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer | Pancreatic Cancer; PDAC; Pancreatic Ductal Adenocarcinoma | active not recruiting | 62 |
| 2027-02-14 est. | P1/P2 | Beijing Biotech | NCT07480928 Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease | recruiting | 42 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-17 est. | P2 | AstraZeneca AZN | NCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarci | recruiting | 226 |
| 2026-11 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06767813 Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms | Pancreatic Neoplasms | recruiting | 80 |
| 2026-10-31 est. | P2 | Astellas Pharma Global Development, Inc. | NCT03816163 A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer | Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma | active not recruiting | 393 |
| 2026-10-29 | P2 | Hoffmann-La Roche | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusio | Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, | completed | 534 |
| 2026-10-01 est. | P2 | Taiho Oncology, Inc. | NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Ade | active not recruiting | 53 |
| 2026-08-31 est. | P1/P2 | Verastem, Inc. VSTM | NCT05669482 Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer | KRAS Activating Mutation; Metastatic Cancer; Pancreas Cancer; Neoplasms Pancreatic; Malignant Neopla | active not recruiting | 40 |
| 2026-08-29 est. | P2/P3 | Panbela Therapeutics, Inc. | NCT05254171 Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer | Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage IV | recruiting | 600 |
| 2026-08 est. | P2 | Cornerstone Pharmaceuticals CLM | NCT06518538 Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer | Pancreatic Cancer Stage IV | withdrawn | |
| 2026-08 est. | P1/P2 | AtlasMedx, Incorporated | NCT04503265 A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | Advanced Malignant Neoplasm; Breast Cancer; Ovarian Cancer; Homologous Recombination Deficiency; Pro | recruiting | 122 |
| 2026-07-28 est. | P1/P2 | Lantern Pharma Inc. LTRN | NCT05933265 Study of LP-184 in Patients With Advanced Solid Tumors | Advanced Solid Tumor; Metastatic Solid Tumor; GBM; TNBC - Triple-Negative Breast Cancer; NSCLC; Panc | active not recruiting | 64 |
| 2026-07-15 est. | P2 | Can-Fite BioPharma CANF | NCT06387342 Namodenoson Treatment of Advanced Pancreatic Cancer | Pancreatic Adenocarcinoma; Pancreatic Cancer | recruiting | 20 |
| 2026-07 est. | P1/P2 | Prestige Biopharma Limited PBH | NCT05141149 First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer | Pancreatic Cancer | active not recruiting | 80 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
| 2026-06-01 est. | P2/P3 | Oncotelic Inc. OTLC | NCT06079346 A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | recruiting | 455 |
| 2026-06-01 est. | P1/P2 | Alligator Bioscience AB | NCT04888312 Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients | Metastatic Pancreatic Ductal Adenocarcinoma | active not recruiting | 94 |
| 2026-06 est. | P3 | Revolution Medicines, Inc. RVMD | NCT06625320 Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma | active not recruiting | 500 |
| 2026-06 est. | P1/P2 | CG Pharmaceuticals, Inc | NCT05249101 A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | active not recruiting | 70 |
| 2026-06 est. | P2 | Actuate Therapeutics Inc. ACTU | NCT03678883 9-ING-41 in Patients With Advanced Cancers | Cancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractory | active not recruiting | 350 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "pancreatic cancer"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.